Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart C Gordon

Showing results (201-210 of 214) with videos related to

Pageof 22
Sort By:
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Journal of Hepatology|July 28, 2014
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infectionAndrew J Muir, Sanjeev Arora, Gregory Everson, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trialMichael Trauner, Cynthia Levy, Atsushi Tanaka, et al.
Journal of Viral Hepatitis|January 5, 2023
Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™Zobair M Younossi, Ming-Lung Yu, Yusuf Yilmaz, et al.
Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
Journal of Hepatology|August 30, 2024
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis BMaria Buti, Jeong Heo, Yasuhito Tanaka, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 12, 2021
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) RegistryZobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, et al.
Pageof 22

Showing results (201-210 of 214) with videos related to

Sort By:
Pageof 22
The New England Journal of Medicine|April 15, 2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infectionNezam Afdhal, K Rajender Reddy, David R Nelson, et al.
The New England Journal of Medicine|April 12, 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosisKris V Kowdley, Stuart C Gordon, K Rajender Reddy, et al.
Journal of Hepatology|July 28, 2014
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infectionAndrew J Muir, Sanjeev Arora, Gregory Everson, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trialMichael Trauner, Cynthia Levy, Atsushi Tanaka, et al.
Journal of Viral Hepatitis|January 5, 2023
Clinical and patient-reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™Zobair M Younossi, Ming-Lung Yu, Yusuf Yilmaz, et al.
Journal of Hepatology|April 3, 2022
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitisChristopher L Bowlus, Michael R Galambos, Richard J Aspinall, et al.
Journal of Hepatology|August 30, 2024
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis BMaria Buti, Jeong Heo, Yasuhito Tanaka, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 12, 2021
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) RegistryZobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, et al.
Pageof 22